CHM chimeric therapeutics limited

Ann: CLTX CAR T data shows regional control of tumour recurrence, page-25

  1. 318 Posts.
    lightbulb Created with Sketch. 229
    100% Arcus - and it's fascinating learning about it! So much potential here and it will be recognised some enough. Talking about IMU, the exact same thing happened over there at a similar stage. Once the circles get a hold of what the recent data actually means and we get closer to more newsflow, pipeline additions, regulatory milestone announcements we will see a re-rate and it will come quickly IMHO. It was interesting in yesterdays NWR Healthcare event presentation Jen mentioned growing the pipeline with NK Cells and Macrophages again twice. There is a company out of the US (private company - Seed round funded) who have seen some good data from their Phase I Car-Macrophage trials. 101 has some serious promise, and I haven't had much time at all lately to do research but I wonder if we could arm a Car-Macrophage with CLTX would it provide another shot on goal?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $20.21K 5.053M

Buyers (Bids)

No. Vol. Price($)
2 2213046 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 13563373 20
View Market Depth
Last trade - 15.01pm 24/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.